International urology and nephrology · 2025
The current clinical management of muscle wasting in hemodialysis patients with end-stage renal disease.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Shiyu, Zhang Lingge, Wu Hao, Li Lu
Аннотация
OBJECTIVES: Currently, the proportion of haemodialysis patients with combined sarcopenia is as high as 13.7%, and the prevalence of sarcopenia in patients over 60 years of age is 33.3%. At present, the pathogenesis of combined sarcopenia in dialysis patients and the intervention strategies are still unclear, and the aim of this paper is to explore the pathogenesis of sarcopenia in haemodialysis patients and the clinical management strategies to improve the patients' prognosis and quality of life.
METHODS: The relationship between sarcopenia and microinflammation and protein metabolic imbalance was analysed and the effects of nutritional supplementation, exercise and pharmacological treatment were assessed.
CONCLUSIONS: The management of sarcopenia, which is critical for improving quality of life in haemodialysis patients, is associated with multiple factors, including microinflammation, reduced protein synthesis, and hormonal dysregulation. This article proposes an integrated management strategy of diet, exercise and pharmacotherapy and explores new therapeutic targets such as methylglyoxal to improve patient prognosis.
METHODS: The relationship between sarcopenia and microinflammation and protein metabolic imbalance was analysed and the effects of nutritional supplementation, exercise and pharmacological treatment were assessed.
CONCLUSIONS: The management of sarcopenia, which is critical for improving quality of life in haemodialysis patients, is associated with multiple factors, including microinflammation, reduced protein synthesis, and hormonal dysregulation. This article proposes an integrated management strategy of diet, exercise and pharmacotherapy and explores new therapeutic targets such as methylglyoxal to improve patient prognosis.